A Novel Nanosafety Approach Using Cell Painting, Metabolomics, and Lipidomics Captures the Cellular and Molecular Phenotypes Induced by the Unintentionally Formed Metal-Based (Nano)Particles.

additive manufacturing high-content screening (HCS) inflammation multivariate analysis nanoparticle emissions new approach methodologies (NAMs) targeted metabolomics

Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
11 01 2023
Historique:
received: 06 12 2022
revised: 01 01 2023
accepted: 09 01 2023
entrez: 21 1 2023
pubmed: 22 1 2023
medline: 25 1 2023
Statut: epublish

Résumé

Additive manufacturing (AM) or industrial 3D printing uses cutting-edge technologies and materials to produce a variety of complex products. However, the effects of the unintentionally emitted AM (nano)particles (AMPs) on human cells following inhalation, require further investigations. The physicochemical characterization of the AMPs, extracted from the filter of a Laser Powder Bed Fusion (L-PBF) 3D printer of iron-based materials, disclosed their complexity, in terms of size, shape, and chemistry. Cell Painting, a high-content screening (HCS) assay, was used to detect the subtle morphological changes elicited by the AMPs at the single cell resolution. The profiling of the cell morphological phenotypes, disclosed prominent concentration-dependent effects on the cytoskeleton, mitochondria, and the membranous structures of the cell. Furthermore, lipidomics confirmed that the AMPs induced the extensive membrane remodeling in the lung epithelial and macrophage co-culture cell model. To further elucidate the biological mechanisms of action, the targeted metabolomics unveiled several inflammation-related metabolites regulating the cell response to the AMP exposure. Overall, the AMP exposure led to the internalization, oxidative stress, cytoskeleton disruption, mitochondrial activation, membrane remodeling, and metabolic reprogramming of the lung epithelial cells and macrophages. We propose the approach of integrating Cell Painting with metabolomics and lipidomics, as an advanced nanosafety methodology, increasing the ability to capture the cellular and molecular phenotypes and the relevant biological mechanisms to the (nano)particle exposure.

Identifiants

pubmed: 36672217
pii: cells12020281
doi: 10.3390/cells12020281
pmc: PMC9856453
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Nat Protoc. 2016 Sep;11(9):1757-74
pubmed: 27560178
J Nanopart Res. 2014;16:2493
pubmed: 25076842
PLoS One. 2014 Dec 05;9(12):e113840
pubmed: 25478795
Nanomaterials (Basel). 2020 Jan 06;10(1):
pubmed: 31935871
Biochim Biophys Acta Mol Cell Biol Lipids. 2022 Jan;1867(1):159066
pubmed: 34626791
Nanotoxicology. 2015 May;9(4):462-73
pubmed: 25119419
Toxicology. 2022 Feb 15;467:153100
pubmed: 35032623
J Immunol. 2021 Sep 15;207(6):1627-1640
pubmed: 34433619
Curr Opin Cell Biol. 2016 Aug;41:25-32
pubmed: 27062546
Biostatistics. 2007 Jan;8(1):118-27
pubmed: 16632515
Biointerphases. 2015 Mar 29;11(1):018901
pubmed: 26514345
Curr Opin Cell Biol. 2021 Feb;68:28-36
pubmed: 32961383
Chem Res Toxicol. 2021 Feb 15;34(2):422-437
pubmed: 33522793
Part Fibre Toxicol. 2012 Jun 14;9:20
pubmed: 22697169
Cell Metab. 2019 Apr 2;29(4):1003-1011.e4
pubmed: 30773464
Ann N Y Acad Sci. 2004 Apr;1011:112-22
pubmed: 15126289
Front Toxicol. 2022 Sep 28;4:981701
pubmed: 36245792
Front Immunol. 2018 Jan 29;9:38
pubmed: 29434586
J Nanobiotechnology. 2017 Nov 21;15(1):84
pubmed: 29157261
Mol Omics. 2019 Feb 11;15(1):30-38
pubmed: 30560257
Mol Biol Cell. 2022 May 15;33(6):ar49
pubmed: 35353015
Toxicol Sci. 2012 Jan;125(1):285-98
pubmed: 22003191
PLoS One. 2013 Dec 02;8(12):e80999
pubmed: 24312513
Science. 2006 Feb 3;311(5761):622-7
pubmed: 16456071
Biochem Biophys Res Commun. 2017 Jan 15;482(3):388-398
pubmed: 28212723
Toxicol Res (Camb). 2019 Jul 24;8(5):711-722
pubmed: 31588348
Toxicol Sci. 2017 Jan;155(1):213-223
pubmed: 27701121
Arch Toxicol. 2012 Jul;86(7):1123-36
pubmed: 22407301
Sci Rep. 2017 Jun 22;7(1):4085
pubmed: 28642468
J Hazard Mater. 2015 Apr 28;287:217-24
pubmed: 25661168
Nucleic Acids Res. 2018 Nov 2;46(19):e116
pubmed: 30011038
Biomed Res Int. 2014;2014:498420
pubmed: 25165707
Commun Biol. 2022 Aug 23;5(1):858
pubmed: 35999457
Part Fibre Toxicol. 2014 Feb 17;11:11
pubmed: 24529161
Metabolites. 2020 May 07;10(5):
pubmed: 32392884
Regul Toxicol Pharmacol. 2013 Feb;65(1):135-46
pubmed: 23142754
Methods Mol Biol. 2019;1888:115-126
pubmed: 30519943
Chem Biol Interact. 2020 May 25;323:109063
pubmed: 32224134
Adv Exp Med Biol. 2022;1357:179-194
pubmed: 35583645
Part Fibre Toxicol. 2020 May 25;17(1):16
pubmed: 32450889
BMC Biol. 2021 Aug 2;19(1):156
pubmed: 34334126
BMC Bioinformatics. 2021 Sep 10;22(1):433
pubmed: 34507520
Front Immunol. 2014 Oct 27;5:532
pubmed: 25386178
Chem Soc Rev. 2020 Aug 7;49(15):5178-5224
pubmed: 32642749
Small. 2020 May;16(21):e1907483
pubmed: 32239645
Int Rev Immunol. 2013 Jun;32(3):249-70
pubmed: 23617726
J Hazard Mater. 2021 Jul 5;413:125273
pubmed: 33581669
Chem Soc Rev. 2021 May 7;50(9):5397-5434
pubmed: 33666625
Sci Total Environ. 2022 Aug 1;832:155058
pubmed: 35390365
Curr Environ Health Rep. 2017 Jun;4(2):223-228
pubmed: 28417441
Sci Rep. 2020 Aug 7;10(1):13320
pubmed: 32770112
Nat Commun. 2022 Mar 25;13(1):1590
pubmed: 35338121
Nanotoxicology. 2018 Aug;12(6):602-620
pubmed: 29790399
Sci Adv. 2022 Nov 04;8(44):eabn5631
pubmed: 36322666
Cell Chem Biol. 2022 Jun 16;29(6):1053-1064.e3
pubmed: 34968420
Biochemistry. 2018 Jan 9;57(1):72-80
pubmed: 29188717
J Electron Microsc Tech. 1990 Nov;16(3):235-9
pubmed: 2243279
J Biomed Mater Res A. 2011 Jan;96(1):186-95
pubmed: 21105167
Langmuir. 2012 Nov 27;28(47):16318-26
pubmed: 22921268
Nanotoxicology. 2019 Dec;13(10):1293-1309
pubmed: 31418618
Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):E751-E760
pubmed: 28096401
Cell Signal. 2020 May;69:109553
pubmed: 32018056
Nanomedicine. 2009 Dec;5(4):473-9
pubmed: 19523415
Small. 2020 May;16(21):e2000598
pubmed: 32363795
Part Fibre Toxicol. 2011 Feb 09;8(1):8
pubmed: 21306632
Antioxidants (Basel). 2022 Oct 08;11(10):
pubmed: 36290718
Science. 2007 Jun 22;316(5832):1753-6
pubmed: 17588932
Nature. 2012 Apr 29;485(7397):201-6
pubmed: 22575960
Toxicol Res (Camb). 2020 Sep 24;9(5):636-651
pubmed: 33178424
Microsc Res Tech. 1994 Feb 15;27(3):198-219
pubmed: 8204911
Mol Pharm. 2016 Jul 5;13(7):2578-87
pubmed: 27287467
Bioact Mater. 2021 Jun 03;7:112-125
pubmed: 34466721
PLoS One. 2016 Jul 19;11(7):e0159684
pubmed: 27434640
Regul Toxicol Pharmacol. 2019 Aug;106:15-26
pubmed: 31028796
Nano Lett. 2014 Mar 12;14(3):1202-7
pubmed: 24555574
Mol Biol Cell. 2021 Apr 19;32(9):995-1005
pubmed: 33534641
Toxicol Sci. 2016 Mar;150(1):190-203
pubmed: 26719371
Biophys J. 2013 Jul 16;105(2):310-9
pubmed: 23870252
Proc Natl Acad Sci U S A. 1979 Sep;76(9):4498-502
pubmed: 291981
Stat Appl Genet Mol Biol. 2010;9:Article17
pubmed: 20361856
Part Fibre Toxicol. 2009 Jun 21;6:17
pubmed: 19545397
Chem Res Toxicol. 2017 Apr 17;30(4):870-882
pubmed: 28362102
SLAS Discov. 2019 Apr;24(4):466-475
pubmed: 30641024
Curr Opin Cell Biol. 2006 Aug;18(4):429-37
pubmed: 16781133
Chembiochem. 2020 Nov 16;21(22):3197-3207
pubmed: 32618075
Chem Biol Interact. 2020 Jan 25;316:108935
pubmed: 31870842
Chem Soc Rev. 2017 Jul 17;46(14):4218-4244
pubmed: 28585944
Small. 2020 Feb;16(6):e1904749
pubmed: 31913582
Toxicol Appl Pharmacol. 2020 Jan 15;389:114876
pubmed: 31899216
Signal Transduct Target Ther. 2020 May 15;5(1):58
pubmed: 32409655
Integr Environ Assess Manag. 2010 Jul;6(3):456-68
pubmed: 20821707
Front Toxicol. 2022 Apr 25;4:836447
pubmed: 35548681
ALTEX. 2013;30(2):209-25
pubmed: 23665807
Nanomedicine (Lond). 2016 Feb;11(3):269-87
pubmed: 26787429
BMC Bioinformatics. 2010 Jul 23;11:395
pubmed: 20650010
Front Cell Dev Biol. 2021 Jun 04;9:670711
pubmed: 34150765
Ann Work Expo Health. 2022 Feb 18;66(2):163-177
pubmed: 34486024
Science. 2006 Sep 29;313(5795):1929-35
pubmed: 17008526
Genome Biol. 2006;7(10):R100
pubmed: 17076895

Auteurs

Andi Alijagic (A)

Man-Technology-Environment Research Center (MTM), Örebro University, SE-701 82 Örebro, Sweden.
Inflammatory Response and Infection Susceptibility Centre (iRiSC), Faculty of Medicine and Health, Örebro University, SE-701 82 Örebro, Sweden.
Faculty of Medicine and Health, School of Medical Sciences, Örebro University, SE-701 82 Örebro, Sweden.

Nikolai Scherbak (N)

Man-Technology-Environment Research Center (MTM), Örebro University, SE-701 82 Örebro, Sweden.

Oleksandr Kotlyar (O)

Man-Technology-Environment Research Center (MTM), Örebro University, SE-701 82 Örebro, Sweden.
Centre for Applied Autonomous Sensor Systems (AASS), Mobile Robotics and Olfaction Lab (MRO), Örebro University, SE-701 82 Örebro, Sweden.

Patrik Karlsson (P)

Department of Mechanical Engineering, Örebro University, SE-701 82 Örebro, Sweden.

Xuying Wang (X)

KTH Royal Institute of Technology, Department of Chemistry, Division of Surface and Corrosion Science, SE-100 44 Stockholm, Sweden.

Inger Odnevall (I)

KTH Royal Institute of Technology, Department of Chemistry, Division of Surface and Corrosion Science, SE-100 44 Stockholm, Sweden.
AIMES-Center for the Advancement of Integrated Medical and Engineering Sciences at Karolinska Institutet and KTH Royal Institute of Technology, SE-100 44 Stockholm, Sweden.
Department of Neuroscience, Karolinska Institutet, SE-171 77 Stockholm, Sweden.

Oldřich Benada (O)

Institute of Microbiology of the Czech Academy of Sciences, 140 00 Prague, Czech Republic.

Ali Amiryousefi (A)

Faculty of Medicine and Health, School of Medical Sciences, Örebro University, SE-701 82 Örebro, Sweden.

Lena Andersson (L)

Inflammatory Response and Infection Susceptibility Centre (iRiSC), Faculty of Medicine and Health, Örebro University, SE-701 82 Örebro, Sweden.
Faculty of Medicine and Health, School of Medical Sciences, Örebro University, SE-701 82 Örebro, Sweden.
Department of Occupational and Environmental Medicine, Örebro University Hospital, SE-701 85 Örebro, Sweden.

Alexander Persson (A)

Inflammatory Response and Infection Susceptibility Centre (iRiSC), Faculty of Medicine and Health, Örebro University, SE-701 82 Örebro, Sweden.
Faculty of Medicine and Health, School of Medical Sciences, Örebro University, SE-701 82 Örebro, Sweden.

Jenny Felth (J)

Uddeholms AB, SE-683 85 Hagfors, Sweden.

Henrik Andersson (H)

Uddeholms AB, SE-683 85 Hagfors, Sweden.

Maria Larsson (M)

Man-Technology-Environment Research Center (MTM), Örebro University, SE-701 82 Örebro, Sweden.

Alexander Hedbrant (A)

Inflammatory Response and Infection Susceptibility Centre (iRiSC), Faculty of Medicine and Health, Örebro University, SE-701 82 Örebro, Sweden.
Faculty of Medicine and Health, School of Medical Sciences, Örebro University, SE-701 82 Örebro, Sweden.

Samira Salihovic (S)

Man-Technology-Environment Research Center (MTM), Örebro University, SE-701 82 Örebro, Sweden.
Inflammatory Response and Infection Susceptibility Centre (iRiSC), Faculty of Medicine and Health, Örebro University, SE-701 82 Örebro, Sweden.
Faculty of Medicine and Health, School of Medical Sciences, Örebro University, SE-701 82 Örebro, Sweden.

Tuulia Hyötyläinen (T)

Man-Technology-Environment Research Center (MTM), Örebro University, SE-701 82 Örebro, Sweden.

Dirk Repsilber (D)

Faculty of Medicine and Health, School of Medical Sciences, Örebro University, SE-701 82 Örebro, Sweden.

Eva Särndahl (E)

Inflammatory Response and Infection Susceptibility Centre (iRiSC), Faculty of Medicine and Health, Örebro University, SE-701 82 Örebro, Sweden.
Faculty of Medicine and Health, School of Medical Sciences, Örebro University, SE-701 82 Örebro, Sweden.

Magnus Engwall (M)

Man-Technology-Environment Research Center (MTM), Örebro University, SE-701 82 Örebro, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH